The deal follows a three-year exclusive research collaboration between the companies. Omniose said Tuesday that its platform can streamline vaccine manufacturing and enable more precise molecular design, which can produce a higher-quality vaccine.
AstraZeneca to Acquire Preclinical Biotech Omniose
AstraZeneca has agreed to buy Omniose, adding the preclinical biotech company’s bioconjugation platform to the pharmaceutical group’s infectious disease unit. The companies did not disclose the terms of the acquisition.
When reusing this material a link to Money Talk is required.
Comments (0)
No comments yet. Be the first!